Vigabatrin
Total Payments
$318,071
Transactions
7
Doctors
2
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $536.40 | 1 | 0 |
| 2020 | $317,535 | 6 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $318,071 | 7 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Vigabatrin Tablets, 500 mg, Fasted Pivotal Study | Hikma Pharmaceuticals USA | $157,311 | 0 |
| Vigabatrin Tablets, 500 mg, Fed Pilot Study | Hikma Pharmaceuticals USA | $157,311 | 0 |
| VIGABATRIN REMS PROGRAM | Teva Pharmaceuticals USA, Inc. | $2,913 | 2 |
| A Single-Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Vigabatrin Tablets, 500 mg Compared to Sabril Tablets, 500 mg, under Fasted Conditions | Hikma Pharmaceuticals USA | $536.40 | 0 |
Ad
Manufacturing Companies
- Hikma Pharmaceuticals USA $315,158
- Teva Pharmaceuticals USA, Inc. $2,913
Product Information
- Type Drug
- Total Payments $318,071
- Total Doctors 2
- Transactions 7
About Vigabatrin
Vigabatrin is a drug associated with $318,071 in payments to 2 healthcare providers, recorded across 7 transactions in the CMS Open Payments database. The primary manufacturer is Hikma Pharmaceuticals USA.
Payment data is available from 2020 to 2021. In 2021, $536.40 was paid across 1 transactions to 0 doctors.
The most common payment nature for Vigabatrin is "Unspecified" ($318,071, 100.0% of total).
Vigabatrin is associated with 4 research studies, including "Vigabatrin Tablets, 500 mg, Fasted Pivotal Study" ($157,311).